Opexa Therapeutics is a biotechnology company focused on developing patient-specific cellular therapies for treating autoimmune diseases like MS. Tcelna, the company’s leading therapy, is a personalized cellular immunotherapy treatment currently in clinical development to target both SP-MS and Relapsing Remitting MS. Tcelna is derived from T-cells that have been isolated from peripheral blood, expanded ex vivo and reintroduced into patients through subcutaneous injections. For more information, visit the company’s Web site at www.opexatherapeutics.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: